{"contentid": 488503, "importid": NaN, "name": "Soriot's ship stays the course in first quarter", "introduction": "Markets welcomed a robust first quarter results statement from AstraZeneca, with the firm reporting revenues of $7.3 billion, an increase of 15% on the same period from last year.", "content": "<p><span style=\"font-weight: 400;\">Markets welcomed a robust first quarter 2021 results statement from AstraZeneca (LSE: AZN), with the firm reporting revenues of $7.3 billion, an increase of 15% on the same period from last year.</span></p>\n<p><span style=\"font-weight: 400;\">Analysts had expected sales to come in below $7 billion, and the firm&rsquo;s share price rose 2% on Thursday, before continuing to rise a further 4% to &pound;77.04 on Friday morning.</span></p>\n<p><span style=\"font-weight: 400;\">Earnings per share (EPS) doubled in the quarter, at $1.19, reflecting the benefit from a lower tax rate as a result of a non-taxable gain from the sale of Viela Bio.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The firm retained a 26.7% stake in the spinout, which was bought in February by Horizon Therapeutics (Nasdaq: HZNP), for $3.05 billion.</span></p>\n<p><span style=\"font-weight: 400;\">Overall, the result were driven by a strong performance across the board, with AstraZeneca&rsquo;s oncology and CVRM - cardiovascular, renal and metabolic - divisions growing 16% and 15%, respectively.</span></p>\n<p><span style=\"font-weight: 400;\">Over half of revenues were contributed by new medicines, and all regions delivered what chief executive Pascal Soriot called &ldquo;encouraging growth.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">AstraZeneca, which has been buffeted by </span><a href=\"https://www.thepharmaletter.com/article/eu-sues-vaccine-developer-while-usa-donates-excess-supplies\"><span style=\"font-weight: 400;\">legal and regulatory challenges</span></a><span style=\"font-weight: 400;\"> surrounding its coronavirus vaccine, is benefiting from a bold, decade-old strategy to invest heavily in R&amp;D.</span></p>\n<p><span style=\"font-weight: 400;\">Mr Soriot said the quarter was marked by &ldquo;strong revenue and earnings progression, continued profitability, and cash-flow generation, despite the pandemic's ongoing negative impact on the diagnosis and treatment of many conditions.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;We expect the impact of COVID to reduce and anticipate a performance acceleration in the second half of 2021.&rdquo;</span></p>\n<h2><strong>Coronavirus impact</strong></h2>\n<p><span style=\"font-weight: 400;\">Unlike other vaccine producers, AstraZeneca has agreed with Oxford University, the developer of its option Vaxzevria, to sell the product on a non-profit basis for the duration of the pandemic.</span></p>\n<p><span style=\"font-weight: 400;\">For this reason, despite having already delivered over 65 million doses, at a cost of $275 million, the impact of the program has been to lower EPS by three cents.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The figures show Vaxzevria costs about $4 per shot, significantly cheaper than most alternatives, raising hopes that the product could help put a stop to the spread of coronavirus in developing countries.</span></p>\n<p><span style=\"font-weight: 400;\">The firm, which plans to ramp up vaccine supplies, said production yields were continuing to improve.</span></p>\n<h2><strong>First quarter developments</strong></h2>\n<p><span style=\"font-weight: 400;\">On the data and regulatory front, the firm highlighted results from the OlympiA Phase III trial, which demonstrated Lynparza's (olaparib) benefit for certain forms of early breast cancer.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">Mr Soriot also pointed to the proposed $30 billion acquisition of Alexion as key to sustaining pipeline progress and accelerating business performance. The firm plans to integrate the Boston-based firm as its rare disease unit and area of expertise.</span></p>\n<p><span style=\"font-weight: 400;\">In mid-April the proposal cleared US Federal Trade Commission (FTC) review, an important milestone, and the deal is expected to close in the third quarter.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The company reiterated its forecast for the full year, on a constant exchange rate (CER) basis, guiding for a revenue increase by a low-teens percentage, accompanied by faster growth in core EPS to between $4.75 and $5.</span></p>\n<h2><strong>Selected product performance</strong></h2>\n<p><span style=\"font-weight: 400;\">Tagrisso (osimertinib) - Up 17% at $1.1 billion.</span></p>\n<p><span style=\"font-weight: 400;\">Imfinzi (durvalumab) - Up 20% at $556 million.</span></p>\n<p><span style=\"font-weight: 400;\">Farxiga (dapagliflozin) - Up 54% at $625 million.</span></p>\n<p><span style=\"font-weight: 400;\">Symbicort (budesonide/formoterol) - Down 13% at $691 million.</span></p>\n<p><span style=\"font-weight: 400;\">Vaxzevria - $275 million.</span></p>", "date": "2021-04-30 10:40:00", "meta_title": NaN, "meta_keywords": "quarter, firm, billion, million, Soriot, AstraZeneca, impact, performance, revenues, share, results, increase, year, coronavirus, vaccine, Vaxzevria, perio", "meta_description": "Markets welcomed a robust first quarter results statement from AstraZeneca, with the firm reporting revenues of $7.3 billion, an increase of 15% on the same per", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 10:39:57", "updated": "2021-04-30 11:31:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/soriot-s-ship-stays-the-course-in-first-quarter", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big-1.jpg", "image2id": "astrazeneca_small-2.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cardio-vascular, Infectious diseases, Oncology, Vaccines", "topic_tag": "Coronavirus, Financial, Focus On, Management", "geography_tag": "UK", "company_tag": "Alexion Pharmaceuticals, AstraZeneca, Viela Bio", "drug_tag": "Farxiga, Imfinzi, Symbicort, Tagrisso, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 10:40:00"}